HEBERT SAM-E

Laboratoires Hébert was a French pharmaceutical company specializing in the development and commercialization of S-adenosyl-L-methionine (SAM-e) based products. The company was a pioneer in the use of SAM-e for various therapeutic indications, including depression, osteoarthritis, and liver disorders. In 2011, the company was acquired by HRA Pharma, which sought to expand its portfolio in niche therapeutic areas and strengthen its position in the French market. Following HRA Pharma's acquisition by Perrigo in 2022, the Hébert brand and its SAM-e products are now part of the Perrigo consumer self-care portfolio. The company's legacy is defined by its focus on high-quality metabolic supplements and specialized pharmaceutical treatments. Its products were widely recognized in the French healthcare system for their efficacy in treating mood disorders and joint health.